Cardiomyopathy genetic research is making strides in Oman through the use of advanced artificial intelligence and genome analysis. A new study led by the National Genetics Centre at the Royal Hospital aims to uncover the genetic roots of cardiomyopathy among Omani families.
Under the leadership of Dr. Ahmed Al Amri, the team developed an AI-powered model called “CardioVar.” This tool analyzes Whole Exome Sequencing (WES) data to identify mutations linked to the disease. Moreover, the model integrates over 50,000 variants associated with cardiomyopathy, supported by a network of AI algorithms for accuracy.
Cardiomyopathy remains a global health concern, particularly due to its genetic complexity. In Oman, limited genetic data has long hindered targeted treatment and early diagnosis. Therefore, cardiomyopathy genetic research is crucial to local healthcare development.
The study focused on families with inherited forms of cardiomyopathy. Consequently, the research achieved an over 80% diagnostic success rate. It revealed both known and newly discovered mutations, some involving genes never previously linked to the disease.
These results not only improve clinical understanding but also pave the way for additional studies. Researchers will now explore the clinical relevance of the new gene mutations. This will further improve diagnosis and treatment protocols for hereditary heart conditions.
The CardioVar model proved highly efficient. It drastically reduced the time needed for data interpretation compared to traditional methods. Furthermore, it boosted accuracy, making it a reliable asset in genetic diagnostics.
Dr. Al Amri emphasized the wider benefits of the project. The model can support genomic medicine across other health conditions. He stated that this type of research offers a roadmap for integrating AI into clinical care nationwide.
The team included Dr. Aisha Al Balushi, Nibras Al Mahrami, Dr. Musallam Al Ariami, and other national experts. Their collaboration brought together medical knowledge, data science, and laboratory expertise.
Together, they have positioned cardiomyopathy genetic research as a national priority. Oman plans to expand this AI-driven diagnostic model to cover other hereditary diseases, moving toward more personalized and effective healthcare solutions.
